Seelos in Agreement with Army Medical Materiel Development Activity on treatment of PTSD

 Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced the signing of a Material Transfer Agreement (MTA) with the U.S. Army Medical Materiel Development Activity (USAMMDA) to supply SLS-002 (intranasal racemic ketamine) for the U.S. Department of Defense's (DOD) Military and Veterans Adaptive Platform Clinical Trial ("M-PACT") to evaluate its potential for treatment of post-traumatic stress disorder (PTSD).

Dosing of the SLS-002 cohort is expected to commence prior to the end of 2024 and it is the only ketamine-based therapy selected for inclusion in this study. The trial is funded by the DOD's Defense Health Agency and led by USAMMDA's Warfighter Readiness, Performance, and Brain Health Project Management Office.

For more information about the M-PACT trial can be found at: https://ptsdclinicaltrial.org/.

https://www.prnewswire.com/news-releases/seelos-therapeutics-announces-the-signing-of-a-material-transfer-agreement-with-us-army-medical-materiel-development-activity-usammda-to-evaluate-sls-002-for-treatment-of-ptsd-302256228.html